Second-generation coronavirus vaccine passes first successful trials New vaccine applicant passes initial safety trials in Manchester. Limited data have been released from the current pre-press study, but experts are cautiously upbeat.

Immunology professor Charles Bangham said:.

"

Safety study conducted in healthy adults who have already received two doses of AstraZeneca vaccine.

Professor Bangham explains that there are two main differences between this new vaccine and the vaccines that are in widespread use..

“First, the vaccine triggers an immune response not only to the SARS-CoV-2 spike protein, but also to some other proteins of the virus.. This is important because the other proteins differ much less between the variants of SARS-CoV-2 than the spike protein, so we would expect more cross-protection from the different variants.. These proteins are well recognized by cytotoxic (“killer”) T cells, and since the T cell response plays an important role in defense, especially in the elimination of the virus from the body, the immunity created by the vaccine should provide good cross protection against variants of the virus.

"

The second benefit of the new vaccine, Banham explains, is not directly related to the immune response, but to the economics and policy of the vaccine.. The new vaccine is based on self-enhancing RNA.

This is amplified to produce large amounts of mRNA, replicating the mRNA found in Pfizer and Moderna vaccines. As it increases, only a small dose is needed - this should allow many more people to be vaccinated with the same amount of vaccine..

https: // www. medikforum. ru /.

Keywords:.